Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease

• Published in: Theranostics 2022-01, Vol.12 (5), p.2095-2114
• Main Authors: Zheng, Yan, Zhang, Limin, Zhao, Jinge, Li, Lingyun, Wang, Minxuan, Gao, Peifeng, Wang, Qing, Zhang, Xiaoling, Wang, Weizhi
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Antibodies; Aptamers, Nucleotide - therapeutic use; Biomarkers; Biosensing Techniques - methods; Cost analysis; Cytotoxicity; Dementia; Humans; Medical diagnosis; Medical research; Nanomaterials; Neurodegenerative Diseases; Peptides; Review; Sensors
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.69465

Alzheimer's disease (AD) is an irreversible neurodegenerative disease, causing profound social and economic implications. Early diagnosis and treatment of AD have faced great challenges due to the slow and hidden onset. β-amyloid (Aβ) protein has been considered an important biomarker and therapeutic target for AD. Therefore, non-invasive, simple, rapid and real-time detection methods for AD biomarkers are particularly favored. With the development of Aβ aptamers, the specific recognition between aptamers and Aβ plays a significant role in AD theranostics. On the one hand, aptamers are applied to construct biosensors for Aβ detection, which provides possibilities for early diagnosis of AD. On the other hand, aptamers are used for regulating Aβ aggregation process, which provides potential strategies for AD treatment. Many excellent reviews have summarized aptamers for neurodegenerative diseases or biosensors using specific recognition probes for Aβ detection applications in AD. In this review, we highlight the crucial role of the design, classification and applications of aptamers on Aβ detection as well as inhibition of Aβ aggregation for AD.